Abstract

The role of the new mometasone + olopatadine combination in the treatment of allergic rhinitis

Allergic rhinitis (AR) is the most common allergic disease across the world. AR is inflammation that displays such major clinical symptoms as a blocked, itchy and/or runny nose, sneezing, nasal congestion as well as itchy and/or watery eyes, burning or stinging in the eyes and eye redness. AR is a troublesome condition associated with a number of coexisting symptoms. Untreated AR results in sleep disorders, fatigue, cognitive impairment and irritability. As a result, the patient’s performance at school/work and their quality of life are significantly diminished.

The treatment of AR is based on the use of topical medications (nasal corticosteroids and antihistamines), oral medications (oral second-generation antihistamines, antileukotrienes) and causal treatment – specific immunotherapy. Based on real-life clinical experience and studies, it can be concluded that a combination therapy based on the use of a nasal corticosteroid and a nasal antihistamine may be considered to be most beneficial. Until now, there has been only one commercially available product (fluticasone + azelastine). Recently, another agent – a combination of mometasone and olopatadine – has been launched. This paper discusses the efficacy and safety of this new drug combination, placing it in the context of other widely available therapeutic options for AR.

Keywords: allergic rhinitis, ARIA, nasal corticosteroids, nasal antihistamines, mometasone/olopatadine

Piśmiennictwo

1. Mims JW. Epidemiology of allergic rhinitis. Int Forum Allergy Rhinol 2014;4(Suppl 2):S18-20. doi: 10.1002/ALR.21385

2. Samoliński B, Raciborski F, Lipiec A, et al. Epidemiologia Chorób Alergicznych w Polsce (ECAP). Epidemiology of allergic diseases in Poland. Otolaryngol Pol 2014;1:10-18. doi: 10.1016/j.alergo.2014.03.008

3. Khan DA. Allergic rhinitis and asthma: epidemiology and common pathophysiology. Allergy Asthma Proc 2014;35:357-61. doi: 10.2500/AAP.2014.35.3794

4. Bernstein DI, Schwartz G, Bernstein JA. Allergic Rhinitis: Mechanisms and Treatment. Immunol Allergy Clin North Am 2016;36:261-78. doi: 10.1016/J.IAC.2015.12.004

5. Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol 2017;140:950-8. doi: 10.1016/j.jaci.2017.03.050

6. Dierick BJH, van der Molen T, Flokstra-de Blok BMJ, et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Rev Pharmacoecon Outcomes Res 2020;20:437-53 doi: 10.1080/14737167.2020.1819793

7. Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol 2020;145:70-80.e3. doi: 10.1016/J.JACI.2019.06.049

8. Wise SK, Lin SY, Toskala E, et al. (2018). International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol 2018;8:108. doi: 10.1002/ALR.22073

9. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J. Allergy Clin. Immunol 2008;122(Suppl 2):S1-84. doi: 10.1016/J.JACI.2008.06.003

10. Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. Allergy 2018;73:1763-74. doi: 10.1111/ALL.13406

11. Du K, Qing H, Zheng M, et al. Intranasal antihistamine is superior to oral H 1 antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis. Ann Allergy Asthma Immunol 2020;125:589-96.e3. doi: 10.1016/J.ANAI.2020.06.038

12. Bousquet J, Caimmi DP, Bedbrook A, et al. Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study. Allergy 2017;72:857-65. doi: 10.1111/all.13125

13. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-9.e10. doi: 10.1016/J.JACI.2012.01.077

14. Ryaltris® – charakterystyka produktu leczniczego. https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/43139/characteristic

15. Rosenwasser LJ, O’Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr Med Res Opin 2005;21:1377-87. doi: 10.1185/030079905X56547

16. Patel P, Salapatek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Ann Allergy Asthma Immunol 2019;122:160-6.e1. doi: 10.1016/J.ANAI.2018.10.011

17. Gross GN, Berman G, Amar NJ, et al. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Immunol 2019;122:630-8

18. Segall N, Prenner B, Lumry W, et al. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc 2019;40:301-10. doi: 10.2500/AAP.2019.40.4233

19. Chen R, Zheng D, Zhang Y, et al. Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol 2021. doi: 10.1007/S00405-021-07085-W

Do góry